GleamWall
中文EN

CELC Celcuity Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1603454 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-28.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,192.9%
ROA-42.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets110.2%
Debt / equity—
Current ratio14.62x
Interest coverage-11.94x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$37.52M$31.08M$33.06M$37.63M$30.43M$36.41M$29.76M$33.47M
SG&A expense$39.80M$35.04M$17.44M$11.57M$12.42M$7.59M$6.37M$2.96M
Operating income-$77.32M-$66.12M-$50.51M-$49.20M-$42.85M-$44.01M-$36.13M-$36.43M
Interest expense$2.69M$5.42M$6.08M$6.17M$4.59M$3.20M$3.18M$3.27M
Pretax income-$73.34M-$78.86M-$52.84M-$50.97M-$43.80M-$45.27M-$37.00M-$36.65M
Net income-$73.34M-$78.86M-$52.84M-$50.97M-$43.80M-$45.27M-$37.00M-$36.65M
EBITDA-$77.26M-$66.06M-$50.46M-$49.15M-$42.81M-$43.97M-$36.10M-$36.40M
EPS (basic)-1.33-1.44-0.97—-0.92-1.04-0.86—
EPS (diluted)-1.33-1.44-0.97—-0.92-1.04-0.86—
Weighted avg. shares (diluted)55.14M54.82M54.46M—47.59M43.66M43.05M—
Balance sheet
Cash & equivalents$178.16M$182.05M$145.19M$165.70M$74.25M$46.35M$16.48M$22.52M
Short-term investments$464.54M$572.00M$241.87M$275.79M$380.73M$122.03M$189.21M$212.59M
Inventory$1.48M———————
Current assets$673.96M$775.84M$408.93M$465.66M$475.50M$183.10M$217.60M$244.57M
PP&E, net$901,000$611,000$619,000$499,000$417,000$357,000$358,000$336,000
Intangibles$50.00M$50.00M——————
Total assets$726.87M$828.22M$410.16M$466.56M$476.00M$183.59M$218.13M$245.12M
Current liabilities$46.10M$86.87M$33.21M$44.15M$38.79M$39.94M$32.92M$31.72M
Long-term debt$0$0$137.87M$137.55M$137.22M$105.59M$105.34M$105.09M
Total debt$0$0$137.87M$137.55M$137.22M$105.59M$105.34M$105.09M
Total liabilities$800.91M$841.00M$356.64M$366.00M$359.04M$139.22M$131.46M$129.50M
Shareholders' equity-$74.04M-$12.78M$53.52M$100.56M$116.96M$44.38M$86.67M$115.62M
Net debt-$178.16M-$182.05M-$7.32M-$28.16M$62.96M$59.24M$88.86M$82.58M
Shares outstanding49.12M48.92M48.35M48.24M43.27M38.91M37.84M37.14M
Cash flow statement
Operating cash flow-$66.23M-$55.43M-$55.06M-$36.40M-$44.82M-$36.21M-$35.85M-$27.77M
Capital expenditure$11,000$51,000$249,000$53,000$97,000$39,000$60,000$45,000
Free cash flow-$66.24M-$55.48M-$55.31M-$36.45M-$44.91M-$36.25M-$35.91M-$27.82M
Investing cash flow$60.65M-$330.59M$34.52M$103.41M-$257.61M$65.86M$24.26M$37.56M
Financing cash flow$1.70M$422.87M$34,000$24.44M$330.32M$232,000$5.55M$123,000
Depreciation & amortization$61,000$59,000$47,000$49,000$41,000$40,000$37,000$35,000
Stock-based compensation$10.02M$6.90M$5.33M$9.46M$6.78M$2.70M$2.44M$2.31M

Free plan shows the latest 8 periods; Pro shows all 41 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.